Novartis enters deal to acquire gene therapy company AveXis for $8.7 billionNovartis said on Monday it plans to buy AveXis for $218 per share in a cash deal totaling $8.7 billion.[Collection]

Novartis said on Monday it plans to buy AveXis for $218 per share in a cash deal totaling $8.7 billion.https://www.cnbc.com/2018/04/09/novartis-enters-deal-to-acquire-avexis-for-8-point-7-billion.html